Randomized trial · people
Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetes
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, people with type 2 diabetes on the higher retatrutide doses lost a large share of their body fat, and the share of lean mass lost was in line with other obesity treatments.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 189
- Published
- 2025
- Journal
- Lancet Diabetes Endocrinol
What they tested
The team tested how much total body fat adults with type 2 diabetes lost over 36 weeks on retatrutide, compared with placebo and with dulaglutide.
How the study was done
A body composition substudy of a randomized, double-blind, placebo-controlled phase 2 trial at 42 US centers, with 189 adults with type 2 diabetes and a BMI of 25-50 kg/m2. Over 36 weeks, they got once-weekly shots of retatrutide (0.5 mg up to 12 mg), dulaglutide 1.5 mg, or placebo (a dummy shot), and body fat was measured by DXA, an X-ray body scan.

Model. Individual results vary.
What they found
Total fat mass fell by 4.9% in the retatrutide 0.5 mg arm, 15.2% in the 4 mg arms, 26.1% in the 8 mg arms and 23.2% in the 12 mg arm, against 2.6% with dulaglutide and 4.5% with placebo. Compared with placebo, the least squares mean change was -10.7 for 4 mg (p=0.0013), -21.6 for 8 mg and -18.7 for 12 mg (both p<0.0001), while the 0.5 mg arm did not differ from placebo (p=0.83). The share of weight lost as lean mass was similar to other obesity treatments. Adverse events were similar across groups, stomach and gut effects were the most common, and no one died.
What it doesn’t show
Of the 189 people in the substudy, only 103 finished treatment with scans at both the start and week 36, and the trial was a 36-week phase 2 study in mostly White adults with type 2 diabetes. It was funded by Eli Lilly and Company.
The paper
Coskun et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeksRandomized trial · people · 2022
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.